Search results
7,403 Shares in Pfizer Inc. (NYSE:PFE) Bought by Gerber LLC
ETF DAILY NEWS· 2 days agoGerber LLC bought a new position in Pfizer Inc. (NYSE:PFE – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 7,403 shares of the biopharmaceutical ...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 6 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 7 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 6 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Brown Shipley& Co Ltd Has $592,000 Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoBrown Shipley& Co Ltd reduced its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.9% during the fourth quarter, according to the company in its most recent ...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 6 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer Inc. (NYSE:PFE) Position Increased by V Square Quantitative Management LLC
ETF DAILY NEWS· 3 days agoV Square Quantitative Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 260.1% in the 4th quarter, according to the company in its ...
Pfizer reports data from Phase II multiple myeloma treatment trial
Clinical Trials Arena via Yahoo Finance· 2 days agoPfizer has announced findings from the Phase II MagnetisMM-3 clinical trial of ELREXFIO...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 7 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Morningstar· 1 day agoMerck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products. The Food and Drug ...